BA3 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Very Low Leverage And Strong LiquidityAzenta's debt-to-equity of roughly 0.04 and substantial cash provide durable financial flexibility. This limited leverage reduces refinancing risk, funds quality remediation and modest capex, and allows the company to pursue M&A or absorb temporary losses while working toward sustained profitability.
Durable Recurring Revenue From Biorepositories/servicesBiorepository and outsourced services account for a meaningful, fast-growing portion of revenue and generate recurring fees. That durable service mix smooths top-line cyclicality tied to capital equipment, supports predictable cash flows, and increases customer lifetime value over the medium term.
Meaningful Operational Execution ImprovementsSustained improvements in delivery and RNA-Seq turnaround strengthen customer satisfaction and competitive positioning. Better operations reduce churn, speed adoption of services, and improve fixed-cost absorption, which supports sustainable margin recovery as volumes normalize over several quarters.
Bears Say
Persistent Negative ProfitabilityDespite revenue recovery, continued operating losses and a roughly -30% net margin indicate structural earnings conversion issues. Persistent losses suppress ROE, limit internal reinvestment, and force reliance on cash reserves; without durable margin improvement, long-term shareholder returns remain constrained.
Automated Storage Quality Remediation And Order PushoutsOngoing remediation and delayed multimillion-dollar cryo/automated store orders create structural revenue timing risk and reputational damage. Slower capital adoption reduces long-term instrument replacement cycles and weakens fixed-cost absorption, pressuring margins and booking visibility for multiple quarters.
Large Goodwill ImpairmentsSignificant goodwill write-downs reflect diminished long-term cash-flow expectations from prior acquisitions and reduce balance-sheet cushions. Such impairments often accompany weaker future earnings assumptions and can signal that historical M&A returns will not support previous growth projections, complicating recovery planning.
Azenta News
BA3 FAQ
What was Azenta, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Azenta, Inc.’s market cap?
Azenta, Inc.’s market cap is CHF1.03B.
When is Azenta, Inc.’s upcoming earnings report date?
Azenta, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 9 days.
How were Azenta, Inc.’s earnings last quarter?
Azenta, Inc. released its earnings results on May 05, 2026. The company reported -$0.033 earnings per share for the quarter, missing the consensus estimate of $0.1 by -$0.133.
Is Azenta, Inc. overvalued?
According to Wall Street analysts Azenta, Inc.’s price is currently Undervalued.
Does Azenta, Inc. pay dividends?
Azenta, Inc. does not currently pay dividends.
What is Azenta, Inc.’s EPS estimate?
Azenta, Inc.’s EPS estimate is 0.09.
How many shares outstanding does Azenta, Inc. have?
Currently, no data Available
What happened to Azenta, Inc.’s price movement after its last earnings report?
Azenta, Inc. reported an EPS of -$0.033 in its last earnings report, missing expectations of $0.1. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Azenta, Inc.?
Currently, no hedge funds are holding shares in CH:BA3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF21.57 (― Downside)
CHF21.57 (― Downside)
Blogger Sentiment
Bullish
CH:BA3 Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth CHF133.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Company Description
Azenta, Inc.
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
BA3 Stock 12 Month Forecast
Average Price Target
$21.57